Oral palonosetron noninferior to IV formulation for CINV prevention

the ONA take:

Oral palonosetron is non-inferior to intravenous palonosetron for the prevention of cisplatin-related chemotherapy-induced nausea and vomiting (CINV), according to a study published in the October 2015 issue of the journal Supportive Care in Cancer.

For the study, a team of researchers led by Prof. Dr. med. Meinolf Karthaus of the Department of Hematology and Oncology at Klinikum Neuperlach in Munich, Germany, sought to compare the efficacy and safety of oral palonosetron with intravenous palonosetron for the prevention cisplatin-based highly emetogenic chemotherapy.

Researchers enrolled 743 chemotherapy-naive adults with malignant solid tumors initiating cisplatin-based chemotherapy. Patients were randomly assigned to receive palonosetron 0.50mg orally or 0.25mg intravenously plus oral dexamethasone.

Results showed that the complete response rate in the acute phase was higher than 86% in both treatment arms and the safety profiles were comparable.

Treatment-emergent adverse events related to palonosetron occurred in 3.2% of patients in the oral palonosetron group and 6.5% in the intravenous group.

Oral palonosetron noninferior to IV formulation for CINV prevention
Oral palonosetron is non-inferior to intravenous palonosetron for the prevention of cisplatin-related chemotherapy-induced nausea and vomiting.
This study aims to compare the efficacy and safety of oral palonosetron with intravenous (IV) palonosetron for the prevention of cisplatin-related chemotherapy-induced nausea and vomiting (CINV).
READ FULL ARTICLE From Springer
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs